RT Journal Article
SR Electronic
T1 Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.13.20064436
DO 10.1101/2020.04.13.20064436
A1 Shi, Qianling
A1 Zhou, Qi
A1 Wang, Xia
A1 Liao, Jing
A1 Yu, Yang
A1 Wang, Zijun
A1 Lu, Shuya
A1 Ma, Yanfang
A1 Xun, Yangqin
A1 Luo, Xufei
A1 Li, Weiguo
A1 Fukuoka, Toshio
A1 Ahn, Hyeong Sik
A1 Lee, Myeong Soo
A1 Luo, Zhengxiu
A1 Liu, Enmei
A1 Chen, Yaolong
A1 Li, Qubei
A1 Yang, Kehu
A1 on behalf of COVID-19 evidence and recommendations working group
YR 2020
UL http://medrxiv.org/content/early/2020/04/17/2020.04.13.20064436.abstract
AB Background The COVID-19 outbreak presents a new, life-threatening disease. Our aim was to assess the potential effectiveness and safety of antiviral agents for COVID-19 in children.Methods Electronic databases from their inception to March, 31 2020 were searched for randomized controlled trials, clinical controlled trials and cohort studies of interventions with antiviral agents for children (less than 18 years of age) with COVID-19.Results A total of 23 studies of indirect evidence with 6008 patients were included. The risks of bias in all studies were moderate to high in general. The effectiveness and safety of antiviral agents for children with COVID-19 is uncertain: For adults with COVID-19, lopinavir/ritonavir had no effect on mortality (risk ratio [RR]= 0.77, 95% confidence interval [CI] 0.45 to 1.30) and probability of negative PCR test (RR=0.98, 95 CI% 0.82 to 1.18). Arbidol had no benefit on probability of negative PCR test (RR=1.27, 95% CI 0.93 to 1.73). Hydroxychloroquine was not associated with increasing the probability of negative PCR result (RR=0.93, 95% CI 0.73 to 1.18). For adults with SARS, interferon was associated with reduced corticosteroid dose (weighted mean difference [WMD]=-0.14 g, 95% CI -0.21 to -0.07) but had no effect on mortality (RR=0.72, 95% CI 0.28 to 1.88); ribavirin did not reduce mortality (RR=0.68, 95% CI % 0.43 to 1.06) and was associated with high risk of severe adverse reactions; and oseltamivir had no effect on mortality (RR=0.87, 95% CI 0.55 to 1.38). Ribavirin combined with interferon was also not effective in adults with MERS and associated with adverse reactions.Conclusions There is no evidence showing the effectiveness of antiviral agents for children with COVID-19, and the clinical efficacy of existing antiviral agents is still uncertain. We do not suggest clinical routine use of antivirals for COVID-19 in children, with the exception of clinical trials.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from National Clinical Research Center for Child Health and Disorders (Children's Hospital of Chongqing Medical University, Chongqing, China) (grant number NCRCCHD-2020-EP-01) to [Enmei Liu]; Special Fund for Key Research and Development Projects in Gansu Province in 2020, to [Yaolong Chen]; The fourth batch of “;Special Project of Science and Technology for Emergency Response to COVID-19” of Chongqing Science and Technology Bureau, to [Enmei Liu]; Special funding for prevention and control of emergency of COVID-19 from Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province (grant number No. GSEBMKT-2020YJ01), to [Yaolong Chen].Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data to support the findings of this study was extracted from the included studies, and the reliability was guaranteed.